Overview

A Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of HPN-01 in Healthy Subjects

Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, placebo-controlled first-in-human study in which the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered HPN-01 will be evaluated in healthy subjects
Phase:
Phase 1
Details
Lead Sponsor:
Hepanova Inc.